Haematological cancers in pregnancy

Brenner, Benjamin; Avivi, Irit; Lishner, Michael

doi:10.1016/s0140-6736(11)61348-2

Cited by 160 publications

(152 citation statements)

References 90 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…166 The safety and efficacy of hormonal agents and targeted therapies have not yet been evaluated in well-controlled studies including pregnant women. [165][166][167][180][181][182] Currently, the use of such agents in pregnant women is not recommended.…”

Section: Management Of Cancer During Pregnancymentioning

confidence: 99%

“…Granulocyte-colony stimulating factors for the management of neutropenia and antiemetics for the management of nausea and vomiting have been used in pregnant women without any significant side effects. 166,181,183,184 The panel members acknowledged that the management of cancer during pregnancy poses significant diagnostic and therapeutic challenges for both the patient and the physician. The guidelines recommend that AYA women diagnosed with cancer during pregnancy require individualized treatment from a multidisciplinary team involving medical, surgical, and radiation oncologists, gynecologic oncologists, obstetricians, and perinatologists as appropriate.…”

Section: Management Of Cancer During Pregnancymentioning

confidence: 99%

See 1 more Smart Citation

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

253

194

View full text Add to dashboard Cite

Section: Management Of Cancer During Pregnancymentioning

confidence: 99%

Section: Management Of Cancer During Pregnancymentioning

confidence: 99%

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

253

194

View full text Add to dashboard Cite

“…3,4,[6][7][8] Population-based estimates on the outcome of offspring of cancer survivors are lacking. Most studies on childbirth after cancer are hampered by small numbers, as pregnancy during and after cancer is a relatively rare event.…”

mentioning

confidence: 99%

“…[3][4][5] However, exposure to (the effects of) diagnostic investigations, radiation therapy and systemic treatment before and around the time of birth may have adverse effects on the child. 3,4,[6][7][8] Population-based estimates on the outcome of offspring of cancer survivors are lacking. Most studies on childbirth after cancer are hampered by small numbers, as pregnancy during and after cancer is a relatively rare event.…”

mentioning

confidence: 99%

Mortality among offspring of women diagnosed with cancer: A population‐based cohort study

Verkooijen

Ang

Liu

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

One in five cancers in women is diagnosed prior to and during a woman's fertile years. Our study evaluates mortality risks in offspring of mothers with history of cancer. From the Swedish Multi-generation Register and the Cancer Register, we identified all 174,893 children whose mother had been diagnosed with cancer between 1958 and 2001. We categorized offspring into those born before (>1 year before), around (within 1 year before and after diagnosis) and after (>1 year after) their mother's cancer diagnosis and compared their risks of death (standardized mortality ratios, SMRs) and causes of death to the background population. Overall, offspring of mothers diagnosed with cancer had no increased mortality risk (SMR, 1.00; 95% confidence interval [CI], 0.97-1.03). Increased mortality risks were found in offspring of mothers with tobacco-related cancers (head and neck, thoracic and cervical) (SMR, 1.23; 95% CI, 1.13-1.33), in children born around their mother's diagnosis (SMR, 1.66; 95% CI, 1.25-2.13) and in children born after their mother's hematopoietic cancer diagnosis (SMR, 2.07; 95% CI, 1.10-3.35). Compared to the background population, children born around their mother's diagnosis were more likely to die of congenital and perinatal conditions. Overall, offspring of women diagnosed with cancer were not at increased risk of death, except for certain subgroups. Timing of pregnancy in relation to diagnosis and cancer site modifies mortality risks in the offspring.Eighteen percent of female cancers are diagnosed prior to and during a woman's fertile years.1 About one in 1,000 pregnancies is complicated by a cancer diagnosis 2 and substantial proportion of cancer survivors give birth after their diagnosis (unpublished data). Pregnancy during or after a malignancy has repeatedly been shown not to affect maternal prognosis.3-5 However, exposure to (the effects of) diagnostic investigations, radiation therapy and systemic treatment before and around the time of birth may have adverse effects on the child. 3,4,[6][7][8] Population-based estimates on the outcome of offspring of cancer survivors are lacking. Most studies on childbirth after cancer are hampered by small numbers, as pregnancy during and after cancer is a relatively rare event. As such, these studies are underpowered to pick up small, but real increases in mortality risks in the offspring. Although small effects may not be so relevant on an individual patient level, small increases in risk of complications or death in offspring of cancer patients are important from a public health perspective, especially in the light of the growing number of young cancer survivors and improvement in fertility preservation techniques.With our study, using data of the large population-based Swedish Multi-Generation Registry including over three million families and eleven million individuals, we assess mortality risks in offspring of women with a history of cancer in relation to timing of birth and cancer site. MethodsWe linked data from the Multi-Generation Register (incl...

show abstract

“…Fetal and placental malignancies are rare complications during pregnancy [1]. Malignant congenital tumours of fetal origin, with placental involvement, are less commonly described.…”

Section: Introductionmentioning

confidence: 99%

Congenital Acute Lymphoblastic Leukemia with Placental Involvement: Case Report x

Oliveira¹,

Caldas²

2015

J Preg Child Health

View full text Add to dashboard Cite

The authors describe a case of congenital acute lymphoblastic leukaemia (ALL), with extensive placental involvement, causing intrauterine fetal growth restriction and unexpected fetal demise at 33 weeks. Although unusual, other congenital tumours, including neuroblastoma and hepatoblastoma, can metastasize to the placenta. Congenital malignancy must be considered in the differential diagnosis of an abnormally large placenta. This case emphasizes the important role of careful histopathologic examination of the placenta which, combined with immunohistochemistry and clinicopathologic correlation, may establish the accurate diagnosis.

show abstract

Haematological cancers in pregnancy

Cited by 160 publications

References 90 publications

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Mortality among offspring of women diagnosed with cancer: A population‐based cohort study

Congenital Acute Lymphoblastic Leukemia with Placental Involvement: Case Report x

Contact Info

Product

Resources

About